首页> 外文期刊>Pathology International >Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
【24h】

Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.

机译:复合T淋巴细胞白血病/淋巴瘤和弥漫性大B细胞淋巴瘤:病例报告。

获取原文
获取原文并翻译 | 示例
           

摘要

This report concerns a unique case of a composite lymphoma composed of T-lymphoblastic leukemia/lymphoma (T-LBL) and diffuse large B-cell lymphoma (DLBCL) in a 72-year-old woman with generalized lymphadenopathy, splenomegaly and ascites. Laboratory findings showed increased lactate dehydrogenase and soluble interleukin-2 receptor. The biopsy specimen showed replacement of the normal architecture of the lymph nodes by a tumor containing a dual cell population composed of large lymphocytes and medium-sized lymphocytes. Sheets of large lymphocytes often were punctuated by clusters of medium-sized lymphocytes. Flow cytometry and immunohistochemical analysis showed a composite lymphoma with both T-LBL and DLBCL. The T-LBL expressed CD1a, CD3, CD4, CD8, and terminal deoxynucleotidyl transferase. The DLBCL expressed CD19 and CD20, CD23, bcl-2, bcl-6, MUM1 and immunoglobulin kappa light chain. Polymerase chain reaction detected a monoclonal pattern of T-cell receptor gamma and immunoglobulin heavy chain rearrangements in the same specimen. She received eight cycles of R-CHOP (rituximab+cyclophosphamide, doxorubicin, vincristine, prednisone) therapy and achieved complete remission. She has shown no signs of recurrence 20 months after the diagnosis. We describe here a very unusual and, to the best of our knowledge, an as yet never reported case of a primary composite lymphoma of T-LBL and DLBCL.
机译:该报告涉及一例由T淋巴细胞白血病/淋巴瘤(T-LBL)和弥漫性大B细胞淋巴瘤(DLBCL)组成的复合淋巴瘤的一例,该患者患有一般性淋巴结肿大,脾肿大和腹水。实验室检查结果显示乳酸脱氢酶和可溶性白介素2受体增加。活检标本显示,淋巴结的正常结构被肿瘤取代,该肿瘤包含由大淋巴细胞和中型淋巴细胞组成的双细胞群。大片淋巴细胞常被中型淋巴细胞簇打断。流式细胞仪和免疫组织化学分析显示,T-LBL和DLBCL均构成复合淋巴瘤。 T-LBL表达CD1a,CD3,CD4,CD8和末端脱氧核苷酸转移酶。 DLBCL表达CD19和CD20,CD23,bcl-2,bcl-6,MUM1和免疫球蛋白κ轻链。聚合酶链反应在同一样本中检测到T细胞受体γ和免疫球蛋白重链重排的单克隆模式。她接受了八个周期的R-CHOP(利妥昔单抗+环磷酰胺,阿霉素,长春新碱,泼尼松)治疗,并完全缓解。诊断后20个月,她未见复发迹象。据我们所知,这里我们描述的是一种非常不寻常的病例,据我们所知,这是一例尚未报道的原发性T-LBL和DLBCL复合淋巴瘤病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号